Bacterial urinary tract infection

Summary

Bacterial urinary tract infection (MONDO:0005247) is a disease (an umbrella term covering 8 Mondo subtypes) and 575 clinical trials. Top therapeutic interventions include fosfomycin, nitrofurantoin, and ciprofloxacin. A subtype of bacterial infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 8 Mondo subtypes
• Clinical trials: 575

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	bacterial urinary tract infection
Mondo ID	MONDO:0005247
NCIT	C50791
SNOMED CT	68566005
UMLS	C0729524
MedGen	675826
Anatomy (UBERON)	UBERON:0001008
Is cancer (heuristic)	no

Also known as: bacterial urinary tract infection (disease) · infection, urinary tract · tract, infection of urinary · urinary tract infection · urinary tract infection (disease) · urinary tract infectious disease · UTI

Disease family

This is a subtype of bacterial infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › bacterial urinary tract infection

Related subtypes (51): primary bacterial infectious disease, commensal bacterial infectious disease, opportunistic bacterial infectious disease, chorioamnionitis, Clostridium difficile colitis, bacterial gastritis, bacterial arthritis, bacterial pneumonia, Whipple disease, Aeromonas hydrophila infectious disease, Pectobacterium carotovorum infection, Pseudomonas infection, septic peritonitis, bacterial infectious disease with sepsis, empyema, bacterial sexually transmitted disease, meningococcal infection, pasteurellosis, peritonsillar abscess, pneumonic pasteurellosis, tracheitis, Actinobacillus infectious disease, bacterial conjunctivitis, bacterial endocarditis, bacterial meningitis, Bifidobacteriales infectious disease, haemophilus infectious disease, Proteus infectious disease, pulpitis, rat-bite fever, Rickettsiosis, vibrio infectious disease, Yersinia infectious disease, bacterial myositis, noma, idiopathic severe pneumococcemia, necrotizing soft tissue infection, mycobacterial infectious disease, escherichia coli infection, gram-negative bacterial infections, gram-positive bacterial infections, spirochaetales infections, skin disease caused by bacterial infection, staphylococcal infection, anaerobic bacteria infectious disease, Klebsiella infectious disease, fournier gangrene, botryomycosis, bacterial hemorrhagic fever, Mycoplasmoides infection, Enterococcus infectious disease

Subtypes (8): acute cystitis, neonatal urinary tract infectious disease, urinary bladder tuberculosis, ureter tuberculosis, urethritis, renal tuberculosis, pyelonephritis, gonococcal cystitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 575.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	347
PHASE4	85
PHASE2	50
PHASE3	49
PHASE1	22
EARLY_PHASE1	9
PHASE2/PHASE3	7
PHASE1/PHASE2	6

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04095572	PHASE4	RECRUITING	Alternative Prophylaxis in Female Recurrent Urinary Tract Infections
NCT04444440	PHASE4	RECRUITING	Antibiotic Prophylaxis for Bladder Botox
NCT04807894	PHASE4	RECRUITING	Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo
NCT05206500	PHASE4	RECRUITING	NextGen - Clinical Implication of Next Generation Sequencing
NCT05652374	PHASE4	RECRUITING	Gag Therapy for Recurrent Urinary Tract Infection Assessing Comparability to International Nitrofurantoin Gold Standard Study
NCT05723601	PHASE4	ACTIVE_NOT_RECRUITING	Preference of Women With Recurrent Urinary Tract Infection for Vaginal Estradiol Tablet vs Cream
NCT06353269	PHASE4	ACTIVE_NOT_RECRUITING	Adherence to Vaginal Estrogen Therapy in Hypoestrogenic Women With Recurrent Urinary Tract Infections
NCT06518291	PHASE4	NOT_YET_RECRUITING	COMPARISON OF NITROFURANTOIN WITH FOSFOMYCIN in TREATING CYSTITIS IN WOMEN
NCT06598514	PHASE4	ACTIVE_NOT_RECRUITING	Chlorhexidine Lavage for Recurrent Urinary Tract Infection
NCT06953271	PHASE4	NOT_YET_RECRUITING	Methenamine Hippurate Following Intradetrusor OnabotulinumtoxinA Injection
NCT07106125	PHASE4	NOT_YET_RECRUITING	Antibiotics for Kidney Transplant Recipients
NCT07186465	PHASE4	RECRUITING	Microbiome-Modulating Prophylaxis RCT: Antibiotic vs Gynoflor in Postmenopausal Women With Recurrent Cystitis
NCT07501065	PHASE4	NOT_YET_RECRUITING	Prophylactic Antibiotics for Outpatient Urethral Bulking
NCT07508124	PHASE4	RECRUITING	Topical Steroids to Prevent Recurrent Urinary Tract Infections in Uncircumcised Male Infants: a Pilot Study
NCT07532941	PHASE4	NOT_YET_RECRUITING	Clinical Efficacy of Stopping Oral Antibiotics When Symptoms Stop, Compared to ‘Finishing the Course’
NCT00126698	PHASE4	COMPLETED	Prophylactic Antibiotics on Urethral Catheter Withdrawal
NCT00156546	PHASE4	UNKNOWN	Evaluation of the Effectiveness of Antibiotic Prophylaxis in Children With a Previous Urinary Tract Infection
NCT00481689	PHASE4	COMPLETED	Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aeruginosa And Other Common Uropathogens
NCT00663806	PHASE4	COMPLETED	A Phase IV Study of Cipro XR in Uncomplicated UTI
NCT00669994	PHASE4	COMPLETED	Trial to Evaluate the Efficacy and Safety of Cipro® XR in Treating Female Patients With Lower Urinary Tract Infections
NCT00676533	PHASE4	COMPLETED	Cipro® XR in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections
NCT00809913	PHASE4	COMPLETED	Febrile Urinary Tract Infection Randomized Short Treatment Trial
NCT00869427	PHASE4	TERMINATED	Vitamin C for Prevention of Urinary Tract Infections in the Spinal Cord Injured
NCT00873626	PHASE4	COMPLETED	Treatment’s Duration of Acute Uncomplicated Pyelonephritis
NCT00900653	PHASE4	UNKNOWN	Low Dose Estriol With Lactobacilli Treatment for Preventing Recurrent Urinary Tract Infection in Postmenopausal Women
NCT00965848	PHASE4	COMPLETED	A Safety and Efficacy Study of Doripenem in Participants With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Urinary Tract Infections
NCT00986102	PHASE4	COMPLETED	PROUD Study: A Prospective Study on the Usage Patterns of Doripenem in the Asia Pacific Region
NCT01039545	PHASE4	TERMINATED	Symptomatic Therapy of Uncomplicated Lower Urinary Tract Infections in the Ambulatory Setting.
NCT01063452	PHASE4	WITHDRAWN	Impact of Atkinson Product Design Urinary Slide Valve Versus Standard Catheter Drainage System on Social Functioning
NCT01092351	PHASE4	COMPLETED	Efficacy and Safety of Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infections in Adults
NCT01132131	PHASE4	COMPLETED	Management of Urinary Tract Infections in Primary Care Facilities.
NCT01388413	PHASE4	COMPLETED	Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder
NCT01450800	PHASE4	COMPLETED	Suppressive Therapy With Oral Antibiotics for Prevention of Postoperative Urinary Tract Infection (UTI)
NCT01488955	PHASE4	COMPLETED	Immediate vs. Conditional Use of Antibiotics in Uncomplicated Urinary Tract Infection (UTI) - ICUTI
NCT01543347	PHASE4	WITHDRAWN	Temocillin Use in Complicated Urinary Tract Infections Due to Extended Spectrum Beta-Lactamases (ESBL)/AmpC Enterobacteriaceae
NCT01760109	PHASE4	COMPLETED	Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection
NCT01803191	PHASE4	COMPLETED	Efficacy Study of Prophylaxis With Fosfomycin Versus Ciprofloxacin Prior Prostate Biopsy
NCT01820897	PHASE4	COMPLETED	Efficacy of Fosfomycin-Trometamol in Urinary Tract Infection Prophylaxis After Kidney Transplantation
NCT01871753	PHASE4	COMPLETED	The Bacteriuria in Renal Transplantation (BiRT) Study: A Trial Comparing Antibiotics Versus no Treatment in the Prevention of Symptomatic Urinary Tract Infection in Kidney Transplant Recipients With Asymptomatic Bacteriuria
NCT01881165	PHASE4	WITHDRAWN	Cranberry on Urinary Tract Infections

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
FOSFOMYCIN	4	18
NITROFURANTOIN	4	18
CIPROFLOXACIN	4	15
LEVOFLOXACIN ANHYDROUS	4	14
ERTAPENEM	4	9
GENTAMICIN	4	9
METHENAMINE HIPPURATE	4	8
TRIMETHOPRIM	4	8
OFLOXACIN	4	7
SULFAMETHOXAZOLE	4	7
CEPHALEXIN ANHYDROUS	4	6
IMIPENEM ANHYDROUS	4	6
TAMSULOSIN	4	6
AMIKACIN	4	5
CEFEPIME	4	4
DORIPENEM	4	4
ESTRADIOL	4	4
CEFTRIAXONE	4	3
CLAVULANIC ACID	4	3
MEROPENEM	4	3
PIPERACILLIN	4	3
SOLIFENACIN	4	3
TAZOBACTAM	4	3
AMDINOCILLIN PIVOXIL	4	2
AMPICILLIN	4	2
CHLORHEXIDINE	4	2
CILASTATIN	4	2
FINAFLOXACIN	4	2
NORFLOXACIN	4	2
POVIDONE-IODINE	4	2